NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $14.75 -0.09 (-0.58%) Closing price 11/12/2026 03:59 PM EasternExtended Trading$14.75 0.00 (-0.02%) As of 06:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dr. Reddy's Laboratories Stock (NYSE:RDY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RDY alerts:Sign Up Key Stats Today's Range$14.73▼$14.9450-Day Range$11.54▼$15.0352-Week Range$11.36▼$15.67Volume1.65 million shsAverage Volume2.96 million shsMarket Capitalization$12.31 billionP/E Ratio39.88Dividend Yield0.41%Price Target$492.90Consensus RatingHold Company Overview Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes. Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States. Dr. Reddy’s combines pharmaceutical research and development with manufacturing and commercialization. Its activities include developing generic versions of medicines, producing APIs for its own products and other pharmaceutical companies, and expanding access to treatments in both regulated and emerging markets.AI Generated. May Contain Errors. Read More Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreRDY MarketRank™: 4.19774898573 of 5 starsDr. Reddy's Laboratories scored higher than 84% of companies evaluated by MarketBeat, and ranked 57th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialDr. Reddy's Laboratories has a consensus price target of $492.90, representing about 3,240.8% upside from its current price of $14.75.Amount of Analyst CoverageDr. Reddy's Laboratories has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth28.26% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 28.26% in the coming year, from $0.46 to $0.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 39.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 39.88, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.34.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 3.07. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dr. Reddy's Laboratories' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.09% of the float of Dr. Reddy's Laboratories has been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 7.81.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently decreased by 3.23%, indicating that investor sentiment is improving. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.43%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 16.22%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 10.17% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. News and Social Media3.2 / 5News Sentiment1.09 News SentimentDr. Reddy's Laboratories has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for RDY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by Institutions3.85% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RDY Stock News HeadlinesZacks Research Has Positive Outlook for RDY FY2027 EarningsNovember 9, 2026 | americanbankingnews.comDr.Reddy's Wins Brazil Approval For Generic Ozempic AlternativeNovember 5, 2026 | rttnews.comUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 13 at 1:00 AM | Digest Publishing (Ad)Reddy's Gets Tentative FDA Nod For Twice-Yearly HIV Prevention Shot At $40 A YearNovember 3, 2026 | rttnews.comCritical Review: Neurocrine Biosciences (NASDAQ:NBIX) and Dr. Reddy's Laboratories (NYSE:RDY)November 2, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Dr Reddy’s Laboratories (RDY) and Genmab (GMAB)October 27, 2026 | theglobeandmail.comDr. Reddy's Laboratories: 3 Key Takeaways for Long-Term InvestorsOctober 25, 2026 | fool.comDr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call TranscriptOctober 23, 2026 | seekingalpha.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $14.03 at the start of the year. Since then, RDY shares have increased by 5.2% and is now trading at $14.7540. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Ltd (NYSE:RDY) announced its earnings results on Saturday, October, 24th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.02. The firm had revenue of $903.89 million for the quarter, compared to analysts' expectations of $894.94 million. Dr. Reddy's Laboratories had a net margin of 8.56% and a trailing twelve-month return on equity of 7.91%. Read the conference call transcript. When did Dr. Reddy's Laboratories' stock split? Dr. Reddy's Laboratories shares split on Tuesday, November 5th 2024.The 5-1 split was announced on Thursday, September 12th 2024. The newly created shares were issued to shareholders after the closing bell on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split. Who are Dr. Reddy's Laboratories' major shareholders? Top institutional shareholders of Dr. Reddy's Laboratories include Aikya Investment Management Ltd (1.09%), Robeco Institutional Asset Management B.V. (1.04%), State Street Corp (0.45%) and Bessemer Group Inc. (0.12%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Infosys (INFY), Johnson & Johnson (JNJ), Tata Motors (TTM), Walt Disney (DIS), ICICI Bank (IBN), Qualcomm (QCOM) and Wipro (WIT). Company Calendar Last Earnings10/24/2026Today11/12/2026Next Earnings (Estimated)1/22/2027Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, RDY's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:RDY CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,527Year Founded1984Price Target and Rating Average Price Target for Dr. Reddy's Laboratories$492.90 High Price Target$1,450.00 Low Price Target$13.90 Potential Upside/Downside+3,240.8%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.37 Trailing P/E Ratio39.88 Forward P/E Ratio25.01 P/E Growth3.07Net Income$456 million Net Margins8.56% Pretax Margin9.54% Return on Equity7.91% Return on Assets5.29% Debt Debt-to-Equity Ratio0.03 Current Ratio1.93 Quick Ratio1.40 Sales & Book Value Annual Sales$3.58 billion Price / Sales3.44 Cash Flow$0.84 per share Price / Cash Flow17.52 Book Value$4.87 per share Price / Book3.03Miscellaneous Outstanding Shares834,670,000Free Float817,978,000Market Cap$12.31 billion OptionableOptionable Beta0.31 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:RDY) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
